Average Insider

Where insiders trade, we follow

$NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Rachel L. McMinn
CEO
107
Employees
$35.34
Current Price
$309.94M
Market Cap
52W Low$15.93
Current$35.3491.0% above low, 9.0% below high
52W High$37.27

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells13$166,586.364,800
2 weeksBuys00--All Sells
Sells13$166,586.364,800
1 monthBuys00--All Sells
Sells13$166,586.364,800
2 monthsBuys00--All Sells
Sells15$466,629.5614,400
3 monthsBuys00--All Sells
Sells15$466,629.5614,400
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 2, 2026
Cvijic Christine Mikail
Director
Sale2,531$34.58$87,519.45View Details
Jul 2, 2026
Cvijic Christine Mikail
Director
Sale1,530$35.23$53,897.31View Details
Jul 1, 2026
Cvijic Christine Mikail
Director
Sale739$34.06$25,169.60View Details
May 6, 2026
Cvijic Christine Mikail
Director
Sale4,800$32.44$155,691.84View Details
May 6, 2026
Cvijic Christine Mikail
Director
Sale4,800$30.07$144,351.36View Details
10 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.5.2